

May 19, 2020

Key technicals in domestic crop protection market but still in ban list


The central government had constituted an expert committee to identify the neo-nicotinoid insecticides registered in India in August 2013 and mandated the committee to expand the identification list to 66 technicals, which are banned in other countries but registered for domestic use in India. In that regard, the expert committee, in consultation with the central government, came up with a draft document to ban 27 technicals, which involves the risk to the human. The list has around 10 insecticides, 11 fungicides while the remaining six are from the herbicides portfolio.

Key molecules such as Acephate, Chlorpyriphos, 2,4-D, Malathion, Dimethoate, Mancozeb, Butachlor, Pendimethalin, Altrazine are in the list of ban portfolio. We believe th aforementioned technicals along with other listed technicals in the ban list, have around ~40-50% market share in the domestic crop protection consumption market. Thus, this is an imminent risk to the domestic generic agrochemical industry given the country could have to import patented/branded formulation resulting in an increase in the agri input cost to farmers. The government plans to ban consumption of 27 technicals in India. However, we believe the same can be exported if the destination country has no objection towards its use. Thus, the domestic agrochemical companies would be immune, to a certain extent, given that the domestic agrochemical market has a sizeable market share in the global genetic crop protection industry (however we need some more insights from the government given that this is just a draft document and many provisions are still unclear). The ban list of 27 technicals is estimated to have a market size of around ₹ 5000 crore, of which ~70% is consumed in the domestic market while the rest is exported.

We have Rallis and Sumitomo Chemical in our crop protection chemical coverage basket. Acephate and Pendimethalin are key products in the Rallis portfolio while for Sumitomo Chemical it is Chlorpyriphos. Even if the above technical is banned for domestic market consumption, we do not expect the same to impact the earnings of both these companies adversely given that these technicals may not be sizeable compared to the domestic revenue pie of both players. They can still export those molecules. Thus, overall earnings should not be impacted. We believe there is a high probability that domestic agrochemical/farmer associations would challenge this outcome legally. It would take at least a year for any positive or negative outcome to emerge.







Research Analyst

Chirah Shah shah.chirag@icicisecurities.com

Dhavan Shah dhavan.shah@icicisecurities.com Sector Update

List of molecule	Type of pesticide	Indian manufacturer
Acephate	Insecticide	UPL, Bayer cropscience, Meghmani organics, Rallis
Altrazine	Herbicide	Meghmani organics, Rallis
Benfuracarb	Insecticide	Coromandel international
Butachlor	Herbicide	Insecticide India, Coromandel international
Captan	Fungicide	Bayer cropscience
Carbendaz im	Fungicide	Bayer cropscience, Atul, Meghmani organics
Carbofuran	Insecticide	Rallis
Chlorpyriphos	Insecticide	Sumitomo chemical, Coromandel international, Insecticides India, Meghmani organics
2,4-D	Herbicide	Atul, Meghmani organics, Insecticides India
Deltamethrin	Insecticide	Bayer cropscience, Meghmani organics
Dicofol	Fungicide	Indofil
Dimethoate	Insecticide	Coromandel international, Rallis
Dinocap	Fungicide	
Diuron	Herbicide	Bayer cropscience, Atul, Hikal
Malathion	Insecticide	Rallis, Sumitomo chemical, Coromandel internationa
Mancozeb	Fungicide	Rallis, Coromandel international, UPL
Methomyl	Fungicide	
Monocrotophos	Insecticide	Coromandel international, UPL, Meghmani organics
0 xygluorfen	Herbicide	Bayer cropscience
Pendimethalin	Herbicide	Rallis, UPL
Quinalphos	Insecticide	Hikal, Coromandel international
Sulfosulfuron	Fungicide	Atul, Sumitomo chemical, UPL, Meghmani organics
Thiodicarb	Insecticide	Bayer cropscience, Insecticides India
Thiophanate methy	Fungicide	Rallis, Insecticides India
Thiram	Fungicide	UPL
Zineb	Fungicide	
Ziram	Fungicide	

RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15% Hold: -5% to 15%; Reduce: -15% to -5%; Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

We /l, Chirag Shah, PGDBM; Dhavan Shah MS(Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ00183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.